Shinkai, 156 patient favipiravir late treatment RCT: 37% faster recovery [p=0.01] https://c19p.org/shinkai
copied to clipboard
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4
RCT 156 patients in Japan, 107 treated with favipiravir, showing significant improvement in a composite outcome defined as the time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
|
time to improvement, 37.1% lower, HR 0.63, p = 0.01, treatment 107, control 49, adjusted per study, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
|
|
time to improvement, 58.5% lower, HR 0.41, p = 0.01, treatment 47, control 13, adjusted per study, <5 days from onset of fever, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Shinkai et al., 8/27/2021, Single Blind Randomized Controlled Trial, Japan, Asia, peer-reviewed, 39 authors, average treatment delay 4.8 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.